Liver tumor treatment gets a targeted boost: Drug-Loaded beads take aim at metastases
NCT ID NCT06311851
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new approach for people with liver metastases (cancer that has spread to the liver from elsewhere). Doctors are using a procedure called TACE to deliver the drug bevacizumab directly into the liver's blood vessels, aiming to concentrate the treatment where it's needed most. The study will enroll 40 participants to see if this method is safe and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab (a drug that slows blood vessel growth) delivered directly to liver tumors via a procedure called TACE
What this could lead to
If successful, this could offer a new treatment option for people with liver metastases that haven't responded to other therapies.
What could go wrong
This is an early pilot study with only 40 participants, so results may not apply broadly. The combination of bevacizumab and TACE is new and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pardis Noor Medical Imaging and Cancer Center
RECRUITINGTehran, Tehran Province, 021, Iran
Contact